[HTML][HTML] Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Nature medicine, 2020•nature.com
Abstract Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness,
but some individuals develop severe pneumonia, respiratory failure and death,,–. Studies of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters,–and
nonhuman primates,–have generally reported mild clinical disease, and preclinical SARS-
CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and
lower respiratory tracts in nonhuman primates,–. Here we show that high-dose intranasal …
but some individuals develop severe pneumonia, respiratory failure and death,,–. Studies of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters,–and
nonhuman primates,–have generally reported mild clinical disease, and preclinical SARS-
CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and
lower respiratory tracts in nonhuman primates,–. Here we show that high-dose intranasal …
Abstract
Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death, , –. Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters, – and nonhuman primates, – have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates, –. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis.
nature.com